MAPT and Cognitive impairment: Studies have indicated that MSCs can ameliorate the cognitive impairment displayed in AD not only by directly targeted on classical markers of AD, like AD and tau (Figures 1B–D), but also by regulating the neuroinflammatory processes (Figures 1E–G) and synaptic transmission (Figures 1H–P), as summarized in Figure 1.